ABSTRACT
Background and purpose Brain tumors are among the leading causes of cancer deaths in children. Initial diagnosis based on MR images can be a challenging task for radiologists, depending on the tumor type and location. Deep learning methods could support the diagnosis by predicting the tumor type.
Materials and methods A subset (181 subjects) of the data from “Children’s Brain Tumor Network” (CBTN) was used, including infratentorial and supratentorial tumors, with the main tumor types being low-grade astrocytomas, ependymomas, and medulloblastomas. T1w-Gd, T2-w, and ADC MR sequences were used separately. Classification was performed on 2D MR images using four different off-the-shelf deep learning models and a custom-designed shallow network all pre-trained on adult MR images. Joint fusion was implemented to combine image and age data, and tumor type prediction was computed volume-wise. Matthew’s correlation coefficient (MCC), accuracy, and F1 scores were used to assess the models’ performance. Model explainability, using gradient-weighted class activation mapping (Grad-CAM), was implemented and the network’s attention on the tumor region was quantified.
Results The shallow custom network resulted in the highest classification performance when trained on T2-w or ADC MR images fused with age information, when considering infratentorial tumors only (MCC: 0.71 for ADC and 0.64 for T2-w), and both infra- and supratentorial tumors (MCC: 0.70 for ADC and 0.57 for T2-w).
Conclusion Classification of pediatric brain tumors on MR images could be accomplished using deep learning, and the fusion of age information improved model performance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research was made possible in part due to The Children's Brain Tumor Tissue Consortium (CBTTC) / The children's brain tumor network (CBTN). The study was financed by Swedish Childhood Cancer Foundation (MT2021-0011, MT2022-0013), Joanna Cocozza's Foundation (2023-2024), and Linkoping University's Cancer Strength Area (2022).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Abstract: MCC value for ADC, Table 1 revised, Material and Method section: added more information about models.